Microbot Medical INC 8-K filings

Microbot Medical has successfully raised $2.35 million through a registered direct offering and a concurrent private placement of preferred investment options.

Microbot Medical has received FDA approval to proceed with its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System.

Microbot Medical announced the successful completion of the first phase of its collaboration with Corewell Health, showcasing the technical capabilities of its LIBERTY robotic system for endovascular procedures.

Microbot Medical anticipates receiving FDA 510(k) clearance in the first half of 2025 and CE Mark approval in the second half of 2025, and has posted updated presentation materials on its website.

Microbot Medical reports that its operations in Israel, the USA, and globally remain uninterrupted, and the company is on track to meet its planned regulatory and commercial milestones despite ongoing geopolitical events.

Microbot Medical Inc. has increased the maximum annual bonus for its Chief Financial Officer, Rachel Vaknin, from 25% to 35% of her base salary, effective for the 2024 fiscal year.

Microbot Medical has reached a settlement agreement resolving a 2020 lawsuit, with the cash portion of the settlement covered by the company's insurance.

Microbot Medical has added a Clinical Research Associate to its US team to support its upcoming IDE submission for its first in-human clinical trial of the LIBERTY Endovascular Robotic Surgical System.

Microbot Medical has reinstated annual fees for independent board members and full compensation for its CEO, effective January 1, 2024, after a period of cost reductions.